Shots:

• BlueRock to get an option to license gene circuits emerging from the collaboration for cell therapy products in specific indications. If option exercises- the company will be responsible for conducting pre/clinical and commercialization activities for any candidates incorporating Senti Bio’s licensed gene circuits
• Senti Bio will strengthen BlueRock’s cell+gene platform by developing gene circuits and will be responsible for designing and testing cell state- and disease- specific Smart Sensors and Regulator Dials to be utilized in regenerative therapies
• The collaboration combines BlueRock’s iPSC platform technology and expertise with Senti Bio’s gene circuit technology platform

  Ref: Globe Newswire | Image: Businesswire